Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in In ...

The sale agreement will see Eli Lilly pay up to $1bn to buy SiteOne, ... The acquisition adds to Eli Lilly’s pain pipeline, which includes four candidates. A Phase I trial (ACTRN12624000642583) ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

LLY’s Zacks Rank. Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.. Only $1 to See All Zacks' Buys and Sells ...

INDIANAPOLIS — Indianapolis-based pharmaceutical giant Eli Lilly and Company will invest up to $250 million as part of an expanded partnership with Purdue University announced Friday, May 9. The ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss.. The centerpiece of the agreement is ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion.

Eli Lilly LLY 1.34 % increase; green up pointing triangle agreed to acquire Verve Therapeutics VERV-0.37 % decrease; red down pointing triangle for about $1 billion upfront, adding a potential ...